Since the interaction of SIGMA I with glycosylated PD-L1 leads to inhibition of PD-L1 autophagic degradation in breast and prostate cancer cells, SIGMA I inhibitor IPAG reverses this event leading to increased T cell activity [37]. Here, CD274 is linked to prostate carcinoma.